The Federal Circuit upheld a ruling that Moderna's COVID-19 vaccine does not infringe Alnylam's mRNA patents related to the SM-102 lipid used in Spikevax.

The product is a new vaccine against COVID-19, for use in all adults 65 and older, as well as individuals aged 12-64 years.

A vaccine expert assured Filipinos on Wednesday that all vaccines are safe after the United States Food and Drug ...

In a precedential decision issued June 4, 2025, the U.S. Court of Appeals for the Federal Circuit (CAFC) affirmed a district ...

The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused ...

Moderna convinced a U.S. appeals court on Wednesday to uphold a ruling that undercut patent infringement claims by biotech ...

HHS Secretary Robert F. Kennedy Jr. says Moderna (MRNA) has agreed to do another clinical trial to back its newly approved ...

The U.S. approved a new COVID-19 vaccine made by Moderna late Friday but with limits on who can use it — not a replacement ...

The approval of the mNEXSPIKE vaccine comes less than a week after Health and Human Services Secretary, Robert F. Kennedy Jr. announced the COVID vaccine for healthy children and healthy pregnant ...

The new mRNA vaccine encodes the receptor-binding domain and the N-terminal domain of the SARS-CoV-2 spike protein ...

Shares of Moderna climbed Monday after the Food and Drug Administration approved a new COVID-19 vaccine from the drugmaker.

FDA approves Moderna’s mNEXSPIKE COVID-19 vaccine for high-risk groups Phase 3 trial shows mNEXSPIKE outperforms original ...